Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors

PURPOSE: To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG). METHODS: 17DMAG was given intravenously over 1 hour daily for 5 days (schedule A) or daily for 3 days (schedule B) every 3 weeks. Plasma...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ramanathan, Ramesh K., Egorin, Merrill J., Erlichman, Charles, Remick, Scot C., Ramalingam, Suresh S., Naret, Cynthia, Holleran, Julianne L., TenEyck, Cynthia J., Ivy, S. Percy, Belani, Chandra P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2010
Pynciau:
Original Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849772/
https://ncbi.nlm.nih.gov/pubmed/20177028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0415
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg